Penumbra (NYSE:PEN) Downgraded to “Hold” Rating by Baird R W

Baird R W cut shares of Penumbra (NYSE:PEN) from a strong-buy rating to a hold rating in a report published on Friday morning,Zacks.com reports.

A number of other research firms have also recently issued reports on PEN. Needham & Company LLC downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $374.00 price target on shares of Penumbra in a report on Thursday. BTIG Research cut shares of Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 price objective for the company. in a research report on Thursday. Bank of America upped their price objective on shares of Penumbra from $320.00 to $370.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Leerink Partners lowered shares of Penumbra to a “market perform” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $355.88.

Penumbra Stock Performance

Shares of PEN opened at $350.93 on Friday. The company has a market cap of $13.74 billion, a PE ratio of 83.95, a price-to-earnings-growth ratio of 2.14 and a beta of 0.71. The firm has a 50-day moving average of $303.54 and a 200-day moving average of $269.52. Penumbra has a one year low of $221.26 and a one year high of $352.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. During the same period in the prior year, the firm earned $0.85 EPS. Penumbra’s quarterly revenue was up 17.8% compared to the same quarter last year. As a group, equities analysts forecast that Penumbra will post 3.67 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 186 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total value of $58,151.04. Following the completion of the sale, the director owned 8,230 shares of the company’s stock, valued at $2,573,027.20. The trade was a 2.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Arani Bose sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the transaction, the director owned 258,462 shares in the company, valued at approximately $79,818,234.84. The trade was a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 34,144 shares of company stock worth $10,260,127. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Several institutional investors have recently made changes to their positions in the stock. Mather Group LLC. bought a new position in Penumbra during the 3rd quarter worth $25,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Penumbra during the 2nd quarter worth $30,000. Rothschild Investment LLC acquired a new stake in shares of Penumbra during the 3rd quarter worth $40,000. Parkside Financial Bank & Trust increased its position in shares of Penumbra by 70.2% in the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock worth $41,000 after purchasing an additional 66 shares during the period. Finally, Covestor Ltd raised its stake in Penumbra by 53.0% in the third quarter. Covestor Ltd now owns 179 shares of the company’s stock valued at $46,000 after purchasing an additional 62 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors.

Penumbra News Summary

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.